Epitope mapping of monoclonal antibodies: a comprehensive comparison of different technologies
- PMID: 38010385
- PMCID: PMC10730160
- DOI: 10.1080/19420862.2023.2285285
Epitope mapping of monoclonal antibodies: a comprehensive comparison of different technologies
Abstract
Monoclonal antibodies have become an important class of therapeutics in the last 30 years. Because the mechanism of action of therapeutic antibodies is intimately linked to their binding epitopes, identification of the epitope of an antibody to the antigen plays a central role during antibody drug development. The gold standard of epitope mapping, X-ray crystallography, requires a high degree of proficiency with no guarantee of success. Here, we evaluated six widely used alternative methods for epitope identification (peptide array, alanine scan, domain exchange, hydrogen-deuterium exchange, chemical cross-linking, and hydroxyl radical footprinting) in five antibody-antigen combinations (pembrolizumab+PD1, nivolumab+PD1, ipilimumab+CTLA4, tremelimumab+CTLA4, and MK-5890+CD27). The advantages and disadvantages of each technique are demonstrated by our data and practical advice on when and how to apply specific epitope mapping techniques during the drug development process is provided. Our results suggest chemical cross-linking most accurately identifies the epitope as defined by crystallography.
Keywords: Alanine scan; Epitope mapping; Hydrogen deuterium exchange; cross-linking; hydroxyl radical footprinting; monoclonal antibodies.
Conflict of interest statement
D.L. Hulsik and J. Kreijtz are employed by, and may own stock in, Aduro Biotech Europe who partially provided funding for this study and own stock in Chinook Therapeutics (KDNY). A. Beebe, X. Dang, M. Beaumont, E. Hsieh, G. Ermacov, T. Fischmann, and V. Juan, are employed by, and may own stock in, Merck & Co., Inc., Rahway, NJ, USA, who partially provided funding for this study. A. Nazabal is employed by, and may own stock in, CovalX. Inc, who provided chemical cross-linking data for this study. L. Guelen and H.v. Eenennaam hold patents in Merck Sharpe & Dohme Corp and own Chinook stock.
Figures
Similar articles
-
Epitope Mapping of Antibody-Antigen Interactions with X-Ray Crystallography.Methods Mol Biol. 2018;1785:13-27. doi: 10.1007/978-1-4939-7841-0_2. Methods Mol Biol. 2018. PMID: 29714009 Free PMC article.
-
Research advances in hydrogen-deuterium exchange mass spectrometry for protein epitope mapping.Anal Bioanal Chem. 2021 Apr;413(9):2345-2359. doi: 10.1007/s00216-020-03091-9. Epub 2021 Jan 6. Anal Bioanal Chem. 2021. PMID: 33404742 Review.
-
Determination of Protein Monoclonal-Antibody Epitopes by a Combination of Structural Proteomics Methods.J Proteome Res. 2023 Sep 1;22(9):3096-3102. doi: 10.1021/acs.jproteome.3c00159. Epub 2023 Aug 1. J Proteome Res. 2023. PMID: 37526474 Free PMC article.
-
Epitope and Paratope Mapping of PD-1/Nivolumab by Mass Spectrometry-Based Hydrogen-Deuterium Exchange, Cross-linking, and Molecular Docking.Anal Chem. 2020 Jul 7;92(13):9086-9094. doi: 10.1021/acs.analchem.0c01291. Epub 2020 Jun 10. Anal Chem. 2020. PMID: 32441507 Free PMC article.
-
Advances in mass spectrometry-based epitope mapping of protein therapeutics.J Pharm Biomed Anal. 2022 Jun 5;215:114754. doi: 10.1016/j.jpba.2022.114754. Epub 2022 Apr 6. J Pharm Biomed Anal. 2022. PMID: 35427962 Review.
Cited by
-
A type-specific B-cell epitope at the apex of outer surface protein C (OspC) of the Lyme disease spirochete, Borreliella burgdorferi.Microbiol Spectr. 2025 Apr;13(4):e0288324. doi: 10.1128/spectrum.02883-24. Epub 2025 Feb 14. Microbiol Spectr. 2025. PMID: 39950825 Free PMC article.
-
Interpretation of Hydrogen/Deuterium Exchange Mass Spectrometry.J Am Soc Mass Spectrom. 2024 May 1;35(5):819-828. doi: 10.1021/jasms.4c00044. Epub 2024 Apr 19. J Am Soc Mass Spectrom. 2024. PMID: 38639434 Free PMC article.
-
The Application of Single-Cell Technologies for Vaccine Development Against Viral Infections.Vaccines (Basel). 2025 Jun 26;13(7):687. doi: 10.3390/vaccines13070687. Vaccines (Basel). 2025. PMID: 40733664 Free PMC article. Review.
-
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics.Nat Rev Drug Discov. 2024 Dec;23(12):898-913. doi: 10.1038/s41573-024-01051-x. Epub 2024 Oct 18. Nat Rev Drug Discov. 2024. PMID: 39424922 Review.
-
Hydrogen/Deuterium Exchange Mass Spectrometry: Fundamentals, Limitations, and Opportunities.Mol Cell Proteomics. 2024 Nov;23(11):100853. doi: 10.1016/j.mcpro.2024.100853. Epub 2024 Oct 9. Mol Cell Proteomics. 2024. PMID: 39383946 Free PMC article. Review.
References
-
- Sukumar S, Wilson DC, Yu Y, Wong J, Naravula S, Ermakov G, Riener R, Bhagwat B, Necheva AS, Grein J, et al. Characterization of MK-4166, a clinical agonistic antibody that targets human GITR and inhibits the generation and suppressive effects of T regulatory cells. Cancer Res. 2017;77(16):4378–88. 1439.2016. doi:10.1158/0008-5472.CAN-16-1439. - DOI - PubMed
-
- van Meerten T, Rozemuller H, Hol S, Moerer P, Zwart M, Hagenbeek A, Mackus WJM, Parren PWHI, van de Winkel JGJ, Ebeling SB, et al. HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20low expressing tumor cells that resist Rituximab mediated lysis. Haematologica. 2010;95(12):2063–71. haematol.2010.025783. doi:10.3324/haematol.2010.025783. - DOI - PMC - PubMed
-
- He W, Tan GS, Mullarkey CE, Lee AJ, Lam MMW, Krammer F, Henry C, Wilson PC, Ashkar AA, Palese P, et al. Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proc Natl Acad Sci USA. 2016;113(42):11931. doi:10.1073/pnas.1609316113. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials